Skip to main contentSkip to footer
A finger pointing at a scan
Brighton & Sussex Medical School

Staff Profiles

BSMS > About BSMS > Contact us > Staff > Dr Susan Catt

Dr Susan Catt

Dr Sue Catt

Dr Susan Catt (PhD, MSc, BSc, CPsychol, AFBPsS)

Research Fellow
T: +44 (0)1273 873024
Location: Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Room 7, University of Sussex, Brighton, BN1 9RX

DA: Sharon Marks 
T: +44 (0)1273 873017

Area of expertise: Psychosocial oncology
Research areas: Quality of life; communication; follow-up services; supportive care; caregiver wellbeing; all particularly in oncology but in other non-cancer patient populations too


Dr Susan Catt trained as a nurse at St George’s Hospital, London, did an undergraduate degree in Psychology at Warwick University (1989), a Masters in Research Methods & Statistics (1990) at Reading University and a Doctorate at the Institute if Food Research & Reading University (1996) which investigated the early perceptions and behavioural effects of fats in the diet of human infants. 

Most of Sue's research career has been in psychosocial oncology starting as a post-doc with the former Imperial Cancer Research Fund (now Cancer Research UK) in Edinburgh working with a team developing genetic screening for bowel cancer. Following this she coordinated a study in London for Professors Michael King and Julia Addington-Hall on the attitudes of older people towards end-of-life issues. Since 2002 she has been at Sussex University with Sussex Health Outcomes Research & Education in Cancer (SHORE-C) where she has gained extensive and wide-ranging experience contributing to communication, quality of life and supportive intervention research aimed at helping patients and healthcare professionals.


In the recent past, Sue has been PI for a number of studies including:

  • a Cancer Research UK funded observational study looking at follow-up care for patients with malignant brain tumours
  • a collaborative study with maxillo-facial surgeons and orthodontists at Queen Victoria Hospital-East Grinstead, exploring quality of life and communication with patients having jaw straightening surgery
  • a collaborative study (with a breast cancer survivor & local charity initiator) surveying cancer survivors’ experiences of a community-based cancer-specific exercise programme (CUFITTER study)

She has also recently helped run work: 

  • investigating the care and treatment experiences of women with advanced ovarian cancer (ADVOCATE study) 
  • exploring the value of progression free survival to patients with advanced cancer receiving novel therapies such as anti-angiogenics and monoclonal antibodies (AVALPROFS study)
  • examining the quality of life and information needs of men with metastatic castrate resistant prostate cancer (EXTREQOL study)
  • evaluating the efficacy of a workshop developed to assist clinicians with talking to their patients about risk in the context of genomic tests (TARGET study)

Currently she is a co-investigator/QOL PI for Q-ABC (Quality of Life After Bladder Cancer) a prospective study comparing patient related outcomes following radical surgery or radical radiotherapy for bladder cancer. A collaboration between Brighton and Sussex University Hospitals NHS Trust (BSUH) (collecting clinical outcomes), SHORE-C (collecting QOL data), and the University of Surrey (conducting a health economic evaluation). The study is in set-up with recruitment starting Sept’18. 

She has a number of grant applications in-progress:

  • lead applicant for the ENQUIRE study looking at the effects of brain metastases on quality of life and cognitive function in breast cancer – under review with Breast Cancer Now
  • lead for the psychosocial elements of a Catalyst Brain Met project (6 single arm Phase II studies) collaborative with lead applicant Carlo Palmieri -Professor of Translational Oncology, University of Liverpool) – submitted to Breast Cancer Now
  • co-applicant for Measuring What Matters – measuring the impact of a brain tumour on broader aspects of life and wellbeing for patients and caregivers – to be submitted for consideration by NIHR HS&DR funding programme (lead applicant Dr Valerie Shilling- SHORE-C).

Please visit the relevant sections of the SHORE-C website

Selected publications

Jenkins V, Farewell V, May S, Catt S, Matthews L, Shilling V, Dickson J, Simcock R, Fallowfield L. Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study. Support Care Cancer. 2018 May 29. doi: 10.1007/s00520-018-4273-3. [Epub ahead of print]

Catt SL, Ahmad S, Collyer J, Hardwick L, Shah N, Winchester L. Quality of life and communication in orthognathic treatment. J Orthod. 2018 Jun;45(2):65-70.

Catt S, Sheward J, Sheward E, Harder H. Cancer survivors' experiences of a community-based cancer-specific exercise programme: results of an exploratory survey. Support Care Cancer. 2018 Apr 5. doi: 10.1007/s00520-018-4179-0. [Epub ahead of print]

Jenkins V, Payne H, Mason M, May S, Matthews L, Catt S. EXTREQOL Identifies Ongoing Challenges in Maximising Quality of Survival in Men with Metastatic Castrate-resistant Prostate Cancer. Clin Oncol (R Coll Radiol). 2018 Jun;30(6):331-333.

Catt S, Starkings R, Shilling V, Fallowfield L. Patient-reported outcome measures of the impact of cancer on patients' everyday lives: a systematic review. J Cancer Surviv. 2017 Apr;11(2):211-232.

Fallowfield LJ, Catt SL, May SF, Matthews L, Shilling VM, Simcock R, Westwell S, Jenkins VA. Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits. Support Care Cancer. 2017 Jan;25(1):237-244.

Nikapota A, Cresswell J, Appleyard S, Catt S. Quality of Life after Bladder Cancer: A Prospective Study Comparing Patient-related Outcomes after Radical Surgery or Radical Radiotherapy for Bladder Cancer. Clinical Oncology. 2015;.

Jenkins V, Catt S, Banerjee S, Gourley C, Montes A, Solis-Trapala I et al. Patients’ and oncologists’ views on the treatment and care of advanced ovarian cancer in the UK: results from the ADVOCATE study. Br J Cancer. 2013;108(11):2264-2271.

Fallowfield L, Francis A, Catt S, Mackenzie M, Jenkins V. Time for a low-risk DCIS trial: harnessing public and patient involvement. The Lancet Oncology. 2012;13(12):1183-1185.

Catt S, Chalmers A, Critchley G, Fallowfield L. Supportive follow-up in patients treated with radical intent for high-grade glioma. CNS Oncology. 2012;1(1):39-48.